Wealthfront Advisers LLC Makes New Investment in Novavax, Inc. (NASDAQ:NVAX)

Wealthfront Advisers LLC purchased a new position in shares of Novavax, Inc. (NASDAQ:NVAX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 18,637 shares of the biopharmaceutical company’s stock, valued at approximately $150,000.

Other large investors have also recently bought and sold shares of the company. Shah Capital Management boosted its holdings in shares of Novavax by 13.6% in the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock valued at $89,637,000 after buying an additional 1,333,305 shares during the last quarter. State Street Corp boosted its holdings in shares of Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after buying an additional 1,621,772 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Novavax by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock valued at $44,245,000 after buying an additional 304,159 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Novavax by 26.7% in the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after buying an additional 517,727 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in shares of Novavax by 48.9% in the 3rd quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after buying an additional 656,900 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on NVAX shares. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. TD Cowen raised Novavax to a “hold” rating in a report on Thursday, February 27th. Finally, BTIG Research began coverage on Novavax in a research note on Friday, February 28th. They issued a “buy” rating and a $19.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $18.00.

Insiders Place Their Bets

In other Novavax news, Director James F. Young sold 5,400 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now owns 51,760 shares in the company, valued at $414,080. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.00% of the company’s stock.

Novavax Trading Up 4.9 %

NVAX opened at $8.38 on Tuesday. Novavax, Inc. has a 1-year low of $3.81 and a 1-year high of $23.86. The stock’s fifty day simple moving average is $8.41 and its 200 day simple moving average is $9.62. The stock has a market cap of $1.35 billion, a PE ratio of -3.71, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same quarter in the previous year, the business earned ($1.44) EPS. Equities analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.